Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural intestinal nematode infections in dogs presented as veterinary patients in Europe

Table 4 Summary of success rate following a single oral dose of Credelio Plus against natural nematode infections in dogs presenting to European veterinary clinics

Nematode species	Treatment group^a	Number of dogs	Success rate^b		Difference in success rate
Nematode species	Treatment group^a	Number of dogs	Successful dogs	Success rate (%)	Estimate	95% Confidence interval^c
All nematode species	Credelio Plus Afoxolaner + MO	278 117	254 103	91.4 88.0	3.33 –	(− 3.41, 10.08) –
T. canis	Credelio Plus Afoxolaner + MO	54 19	48 16	88.9 84.2	4.68 –	(− 13.74, 23.09) –
A. caninum	Credelio Plus Afoxolaner + MO	109 42	103 38	94.5 90.5	4.02 –	(− 5.84, 13.88) –
T. vulpis	Credelio Plus Afoxolaner + MO	176 80	161 75	91.5 93.8	− 2.27 –	(− 8.99, 4.45) –

MO milbemycin oxime
^aSingle oral administration of Credelio Plus on Day 0 to provide a dose range of 0.75–1.56 mg/kg bodyweight MO and 20.0–41.5 mg/kg bodyweight lotilaner. Single oral dose of Nexgard Spectra on Day 0 to provide a dose range of 2.50–5.36 mg/kg bodyweight of afoxolaner and 0.50–1.07 mg/kg bodyweight of MO
^bSuccessfully treated dog is one for whom the individual percentage reduction in egg counts at Day 8, relative to Day 0, is at least 90%
^cConfidence interval for the difference (Credelio Plus – Nexgard Spectra) in proportions of two independent samples. Non-inferiority is accepted when the lower limit of the interval is greater than − 15

ISSN: 1756-3305